theratechnologies stockhouse. By continuing to use our service, you agree to our use of cookies. theratechnologies stockhouse

 
 By continuing to use our service, you agree to our use of cookiestheratechnologies stockhouse  This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its

Read More. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. 4% from the stock's current price. 67% from the latest price. Theratechnologies inc. Stockhouse. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. M. View real-time stock prices and stock quotes for a full financial overview. Contact Email communications@theratech. We also use them to share usage. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Cookies are used to offer you a better browsing experience and to analyze our traffic. - Q3 2022 Consolidated. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Headquarters. Learn why it. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies to Announce Financial Results for Its First Quarter 2022. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 71. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Competitors: Unknown. The reported ($0. stock news by MarketWatch. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. , alpha and beta) for all equities such as Theratechnologies. . For investor inquiries: Leah Gibson. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Us | Theratechnologies Inc. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Unveiling Silvercorp's golden potential at the Ying Mining District. Stockhouse. Cookies are used to. 40 f102M H1. We also use them to share usage. 31K. - Q3 2022 Consolidated Revenue Growth of 17% to $20. 75. Theratechnologies develops and commercializes innovative therapies. MONTREAL, Jan. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. We also use them to share usage. (Image via Theralase Technologies Inc. Heures de négociation. stock news by MarketWatch. (2013-04-03 | TSX:TH) Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Find more information. Stockhouse. By continuing to use our. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. By continuing to use our service, you agree to our use of cookies. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. GUD | Complete Knight Therapeutics Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. 1M. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Herein, we report. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. A high-level overview of Theratechnologies Inc. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 36 morning pop. Thank you. Theratechnologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Stockhouse. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies Inc. RESSOURCES. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Investor Relations. stock price gained 6. 63. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Forecast to breakeven in 2024 Jul 15. 2 million. By continuing to use our service, you agree to our use of cookies. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. 1-438. The abstract and poster can be found on Theratechnologies’ website. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. 9%, while the Biotechs industry saw earnings growing at 17. Market Cap. -based clinical sites participating in the conduct of the Phase. com uses cookies on this site. 81 million for the quarter. T. 33 +0. By continuing to use our service, you agree to our use of cookies. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. : 001-35203 Mr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies had a negative net margin of 36. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Northwest also announces an update on its. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. com uses cookies on this site. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. 11/05/2020 4:15:02 PM. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Jan. 00 to $36. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. L. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 54% and a negative trailing twelve-month return on equity of. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. The price has fallen in 7 of the last 10 days and is down by -30. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. The abstracts are now available at aacr. By continuing to use our service, you agree to our use of cookies. THERATECHNOLOGIES INC. Phone Number 15143319691. T. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. MONTREAL, Jan. Saint-Laurent, Canada. com uses cookies on this site. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. Vice President, Communications and Corporate Affairs. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. (TH. com uses cookies on this site. Follow. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. For investor inquiries: Leah Gibson. com uses cookies on this site. Marsolais will present at the H. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. 23) diluted earnings per. m. These pharmaceuticals. Microsoft to invest $500M in Quebec AI economy. 514-336-7800. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. com uses cookies on this site. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. 1-438. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Inc. THTX | Complete Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. com uses cookies on this site. Investor inquiries: Elif McDonald. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. The company develops treatments for lipodystrophy . 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Biopharmaceutical company Theratechnologies Inc. Paul Levesque - President. 's motion for leave to commence. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. About Theratechnologies. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. Cookies are used to offer you a better browsing experience and to analyze our traffic. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. By continuing to use our service, you agree to our use of cookies. Theratechnologies has generated ($1. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. com uses cookies on this site. Investor inquiries: Elif McDonald. $103. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 22M. Image source: The Motley Fool. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. : Nasdaq Theratechnologies Inc. MONTREAL, Nov. Theratechnologies inc. Stockhouse. 9 million as at August 31, 2023. Theratechnologies Inc. Stockhouse. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. By continuing to use our service, you agree to our use of cookies. Further. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. NEW YORK, Dec. Stockhouse. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. 2% to $21. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. GlobeNewswire. By continuing to use our service, you agree to our use of cookies. 39 50-Day Range $0. Stockhouse. 20% from a day low at $1. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. Stockhouse. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View Company Info for Free. TH | July 20, 2023. acts as investment manager. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. 49) by $0. Theratechnologies Announces 1-for-4 Reverse Stock Split. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. 54% and a negative trailing twelve-month return on equity of 1,116. By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. sBLA for F8 formulation of tesamorelin submitted to FDA. Stockhouse. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. MONTREAL, Nov. European Headquarters. We also use them to share usage information with our partners. - On track to meet FY2022. During the last trading day the stock fluctuated 4. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. “This is yet another major achievement for our oncology program. If you have HIV, it's important to know the difference. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. 17. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. Cookies are used to offer you a better browsing experience and to analyze our traffic. Q3 2023 consolidated revenue of $20. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. Montréal, Québec, Canada . com uses cookies on this site. com uses cookies on this site. 28 $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 49%) At close: 04:00PM EST 1. Theratechnologies Announces 1-for-4 Reverse Stock Split. TH | February 28, 2023. 72%. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. com uses cookies on this site. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. THTX earnings call for the period ending February 29, 2020. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Get the latest Sernova Corp (SVA) real. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . 35 as of 10:41 a. . Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies Inc. ("Theratechnologies" or the "Company"). A high-level overview of Theratechnologies Inc. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. 8 million. e. 08). (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. By Nick Paul Taylor Jul 12, 2023 8:57am. . Stockhouse. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 9 million as at August 31, 2023. MONTREAL, Feb. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. We also use them to share usage. - Q3 2022 North American Revenue Growth of 19%. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 25 to $1. It is the Company’s proprietary peptide linked to. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. com uses cookies on this site. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies had a negative net margin of 36. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 06 million, an increase of 14. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. Theratechnologies Inc. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies Inc. S. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 1. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. Cookies are used to offer you a better browsing experience and to analyze our traffic. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). Cookies are used to offer you a better browsing experience and to analyze our traffic. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. com uses cookies on this site. ir@theratech. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. Senior Director, Investor Relations. 67, which is an increase of 1,144. Theratechnologies Inc. TO) on CEO. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. On average, they expect the company's stock price to reach $36.